All In Biotech

Drug Trial Radar · NCT03457532

A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors

An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characters, and Preliminary Efficacy of SCC244 in Patients with Advanced MET Alterations Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

177

Actual

Start

Dec 16, 2017

Primary completion

Sep 22, 2023

Study completion Sep 22, 2023

Sponsor

Lead sponsor
Haihe Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1a/1b multi-center and open label study to evaluate the safety, tolorability, pharmacokinetics and priliminary efficacy of SCC244 in advanced solid tumors patients with c-MET alteration

Conditions

  • Advanced Solid Tumor

Interventions

  • Gumarontinib TabletsDrug

    25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT(Dose limit toxity)Time frame: 35 days
  2. MTD(Max tolerance does)Time frame: 35 days
  3. BED(Biological effective dose)Time frame: 35 days
  4. objective response rate (ORR)Time frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.